
Fisher& Poyke Healthcare

Goldman Sachs JBWere Australasian Investment Forum New York - 7 March 2006



Investment Highlights

- Leading player in heated humidification systems
- Consistent growth strategy
- Estimated US\$2+ billion and growing market opportunity
- High level of innovation
- Global presence
- Strong financial performance NZSX:FPH, ASX:FPH





Operating Results US\$ H1 FY06


FY06 (6 mths)

	%Revenue	US\$M	% ∆pcp
Operating revenue	100%	95.0	+27%
Gross profit	70.6%	67.1	+24%
SG&A	29.4%	28.0	+27%
R&D	6.2%	5.9	+12%
Fotal Operating Expenses	35.6%	33.9	+24%
Operating Profit	35.0%	33.3	+25%



Markets and Products

- Respiratory
 humidification
- Obstructive sleep apnea
- Neonatal and other



Consumable products represent approx. 58% of core product sales

Revenue by Product 6 months to 30 September 2005



Respiratory Humidification

- Normal airway humidification is bypassed or compromised during ventilation or O₂ therapy
- Mucociliary transport system
 operates less effectively
 - increases risk of infection
 - impairs gas exchange
- Need to deliver gas at physiologically normal levels

 37°C body core temperature
 - 44mg/L 100% saturated



Market Opportunity

- Estimated US\$350+ million market worldwide
 - heated humidifier controllers
 - humidifier chambers
 - breathing circuits and components +
 - unheated humidifiers
 - oxygen therapy supplies
- Opportunity to move technology into O₂ therapy, COPD, xerostomia, insufflation



Humidification Systems

- MR850 Respiratory Humidifier System
 - invasive ventilation, O₂ therapy and non-invasive ventilation
- MR810 Respiratory Humidifier System
 - entry level system
 - ventilation and O₂ therapy
 - optional heated breathing circuit
- HC550 Respiratory Humidifier System
 - invasive ventilation for home use





Single-use Components

- Single-use chambers
 - patented auto filling MR290
 - manual filling models
- Single-use breathing circuits
 - adult and neonatal
 - patented spiral heater wire
 - proprietary dry expiratory tube
 - less condensation
 - delivery of optimal humidity
- Breathing circuit components
 - filters
 - catheter mount
 - weaning kit
- Approx 35 system set-ups used per controller per year
- Consumable growth driving increased revenue growth rate











Expanding Opportunities

- MR880 Humidification System
 - Controller, chamber, breathing circuit, range of single patient use interfaces.
 - Designed for a range of new patient groups, e.g.
 O₂ therapy, COPD, xerostomia.
- MR860 Laparoscopic Humidification System
 - Humidifies the dry CO₂ gas used in 'keyhole' surgery.
 - Improves outcomes by: reduced hypothermia, less post operative pain, less time in recovery room, faster return to normal activities, reduced risk of adhesions.
 - Potential high volume of consumables.



New


New






Obstructive Sleep Apnea

- Temporary closure of airway during sleep
- Can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack
- Estimated US\$1.2+ billion worldwide market, growing 15% - 20%
- Potentially 50-60 million affected worldwide
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
 – key issue with CPAP is compliance
- Humidification provides significant
 acceptance and compliance improvements







CPAP Systems

- HC150 Humidifier
- SleepStyle[™] 200 Convertible and Integrated Flow Generator series
 - greater pressure range, altitude adjustment, enhanced user ergonomics
 - patented Ambient Tracking[™] plus autoadjusting humidification technology
- SleepStyle[™] 600 Integrated Flow Generator series
 - *ThermoSmart*[™] heated breathing tube technology
 - more humidity
 - reduced symptoms, increased comfort





Mask Range

Four interface categories:

- FlexiFit[™]Nasal Masks
 - patented sliding attachment
 - FlexiFit[™] technology
 - new 406 Petite model

• FlexiFit[™]Full Face Mask – under chin seal

- Oracle[™]Oral Mask – proprietary oral interface
- Infinity[™]Direct Nasal Mask – very light





Neonatal and Warming


- Radiant Warmers
 - warmers required in delivery and NICU
 - precise and stable temperature control
 - opportunity in operating room
- Infant CPAP System
 - proprietary bubble CPAP, non-invasive, oscillating pressure
 - lower risk alternative to ventilation
 - high value consumable system
- Infant Resuscitator System
 - precise pressure control
 - consumable resuscitation kit





Research & Development

- 170 engineers, scientists, physiologists
- 6.2% of revenue H1 FY06
- Product pipeline includes
 - Flow generators
 - Masks
 - Humidification system for COPD therapy
 - Respiratory consumables
- Competitive NZ cost base
- 52 US patents, 70 US pending, 97 ROW, 234 ROW pending *



* at 31 Mar 2005



Manufacturing

- Vertically integrated
 - electronics assembly
 - injection moulding
 - motor assembly
- ISO 9001; Class 100,000 controlled environment
- Ample capacity to grow
 - 300,000ft² / 28,000m² facility
 - 100 acres / 40 ha
 - 23,000m² building due for completion mid 2006








Global Presence


- Direct
 - hospitals, home care dealers
 - Sales/support offices in USA/Canada, UK/Ireland, France/Benelux/Italy/ Spain, Germany/Austria/Switzerland, India, Japan, UAE, China, Australia and NZ - 270 staff
 - Ongoing international expansion
- Distributors
 - 100 distributors worldwide 90 countries
- Original Equipment Manufacturers
 - supply most leading ventilator manufacturers



Revenue by Region 6 months to 30 September 2005



Revenue Growth US\$



Growth Drivers

Consistent strategy:

- Continue to improve existing product lines
- Develop complementary products/ consumables
- Target new medical applications
 –e.g. COPD, O₂ therapy, insufflation
- Increase international presence

 –e.g. South America and Scandinavia

